OliX corrects OLX10212 Phase 2a trial approval disclosure, removes New Zealand reference from title

Bitget2026/10/30 08:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

OliX Pharmaceuticals corrected its disclosure on Oct. 30, 2026, removing “New Zealand” from the OLX10212 Phase 2a trial approval title.
The approval came from Australia's Bellberry Human Research Ethics Committee; New Zealand MedSafe clearance remains pending following a Sept. 30, 2026, application.
The trial targets 64 patients with bilateral age-related macular degeneration with geographic atrophy, with completion expected Sept. 30, 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OliX Pharmaceuticals Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030901020), on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

OliX corrects OLX10212 Phase 2a trial approval disclosure, removes New Zealand reference from title

You may also like

Crypto prices